Immunoxel is a botanical immune system modulator. It is used to avoid and combat the common cold and flu and in a number of clinics as a natural immunomodulator in the treatment of TB and HIV in the Eastern part of Europe.
Stirling stated that the clinical trials conducted on Immunoxel to date have demonstrated that ImmunoXel has immunomodulatory actions with clear effects on cytokine levels and on lymphocyte profiles.
Additionally, the findings of the study showed that ImmunoXel reduces lymphocyte apoptosis in a monkey model of HIV infection, but does not affect T cell proliferation marker KI67.
ImmunoXel increases the production of cytokine IL2 in response to a challenge with a viral antigen (SIVenv protein) both in-vitro (culture dish experiment) and in-vivo (chronically SIV-infected monkeys), ImmunoXel amplifies the vaccine-specific T-cell activation and proliferation response in a monkey model of HIV vaccination
Peter Boonen, managing director of Stirling Products, said: “We are very pleased with the results of these studies which were initiated independently to the company through aresearch institute in the US. The continuing studies are designed to better understand the ImmunoXel structural, molecular and cellular mechanics.
“The preliminary study results provided to us support the use of ImmunoXel in the treatment of HIV, and possibly as an adjuvant to certain HIV vaccines under development.”